A5053225263- Health Systems, Economic Evaluations, Quality of Life
- Inflammatory Bowel Disease
- Hepatitis C virus research
- Pharmaceutical Economics and Policy
- Microscopic Colitis
- Liver Disease Diagnosis and Treatment
- Eosinophilic Esophagitis
- Parkinson's Disease Mechanisms and Treatments
- Hydraulic Fracturing and Reservoir Analysis
- Drilling and Well Engineering
- Seismic Imaging and Inversion Techniques
- Pharmaceutical industry and healthcare
- Chronic Lymphocytic Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Dermatology and Skin Diseases
- HIV/AIDS drug development and treatment
- Fluid Dynamics and Vibration Analysis
- Acute Lymphoblastic Leukemia research
- Wind Energy Research and Development
- Adolescent and Pediatric Healthcare
- Hydrocarbon exploration and reservoir analysis
- Uterine Myomas and Treatments
- Ocular Diseases and Behçet’s Syndrome
- Retinal Diseases and Treatments
- Hepatitis B Virus Studies
Tufts Medical Center
2020
University of North Carolina at Chapel Hill
2020
Sage Therapeutics (United States)
2020
University of North Dakota
2014-2016
Vaxine (Australia)
2015
University of California, Davis
2008-2015
Flinders Medical Centre
2015
Analysis Group (United States)
2008-2013
Precision Research (United States)
2012
Mayo Clinic
2008
Abstract This paper outlines the benefits and challenges of utilizing active flow control (AFC) for wind turbines. The goal AFC is to mitigate damaging loads aeroelastic response turbine blades. can be accomplished by sensing changes in operation activating devices adjust sectional lift coefficient and/or local angle attack. Fifteen are introduced, four described more detail. Non‐traditional trailing‐edge flaps, plasma actuators, vortex generator jets microtabs examples that hold promise...
Background:Patients with chronic myeloid leukemia (CML) who do not adhere to treatment may experience suboptimal outcomes.Objective:To examine the association between adherence imatinib and direct healthcare costs resource utilization in a large group of privately insured CML patients.Patients methods:CML patients under age 65 were identified ICD-9 code 205.1X using MarketScan Commercial Claims data 1/1/02 7/31/08. Patients required be continuously enrolled private insurance plan during...
Treatment of chronically ill people constitutes nearly four-fifths US health care spending, but it is hampered by a fragmented delivery system and discontinuities care. We examined the impact coordination approach called Health Buddy Program, which integrates telehealth tool with management for Medicare beneficiaries. evaluated program's on spending patients two clinics in Northwest who were exposed to intervention, we compared their experience that matched controls. found significant...
Endometriosis has been associated with higher rates of various chronic conditions, but its epidemiological data are fragmented and dated. We sought to compare the incidence developing commonly occurring comorbidities among patients without endometriosis in a large, contemporary patient cohort that reflects real-world clinical practice.A women aged 18-49 incident was extracted from 2006-2015 de-identified Clinformatics® DataMart commercial insurance claims database (OptumInsight, Eden...
The comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis (AD) has not been systematically assessed using recent phase 3 data. This network meta-analysis assesses the without addition topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) in adults with AD. systematic literature review searched through 17 May 2021 3/4 trials upadacitinib, interleukin-4 (IL-4), interleukin-13 (IL-13), or JAK compared placebo active intervention and adolescents...
AbbVie provides a free-to-patient patient support program (PSP) to assist adalimumab-treated patients with medication costs, nurse support, injection training, pen disposal, and reminders. The impact of these services on adherence adalimumab direct medical costs associated autoimmune disease has not been assessed.To quantify the relationship between participation in PSP outcomes (adalimumab adherence, persistence, costs) initiating treatment.A longitudinal, retrospective, cohort study was...
The treatment landscape for moderate-to-severe atopic dermatitis (AD) continues to expand. This network meta-analysis (NMA) updates a previously conducted NMA include data from the most recent phase 3 trials assess comparative efficacy of targeted systemic therapies without addition topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) in adults with AD. Data monotherapy lebrikizumab, ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967), were included analyses, along other...
ABSTRACT Multiple studies describe progression, dementia rates, direct and indirect costs, health utility by Hoehn Yahr (H&Y) stage, but research has not incorporated these data into a model to evaluate possible economic consequences of slowing progression. This study aimed the course Parkinson's disease ( PD ) slower rates A Markov was developed show net monetary benefits Four scenarios assuming hypothetical progression were compared base case scenario. systematic literature review...
Background/aims In rare diseases, health-related quality of life (HRQL) data can be difficult to capture. Given the ultrarare nature RPE65 -mediated inherited retinal disease (IRD), it was not feasible recruit a patient sample and collect HRQL prospectively. The objectives this study were develop health state descriptions IRD, estimate associated utilities. Methods Vignette IRD states developed then assessed elicit vignettes ranged from moderate vision loss through hand motion no light...
Voretigene neparvovec-rzyl, the first gene therapy approved by US Food and Drug Administration, was for treatment RPE65-mediated inherited retinal disease (IRD) in December 2017. This is associated with high up-front costs efficacy, although of unknown duration, its cost-effectiveness has not been assessed RPE65 IRD-specific, longitudinal, patient-observation-level data.To assess incremental ratio (ICER) voretigene neparvovec-rzyl compared standard care disease.In this economic analysis, a...
Objectives To evaluate mortality and healthcare utilization effects of an intervention that combined care management telehealth, targeting individuals with congestive heart failure, chronic obstructive pulmonary disease, or diabetes mellitus. Design Retrospective matched cohort study. Setting Northwest United States. Participants High‐cost Medicare fee‐for‐service beneficiaries (N = 1,767) enrolled in two Centers for Medicaid Services demonstration participating clinics a propensity‐score...
The purpose of this study was to describe comorbidities, healthcare costs, and resource utilization among patients with chronic non-infectious uveitis initiating corticosteroid, immunosuppressants, or biologics.In retrospective cohort study, a diagnosis continuous insurance coverage during 6-month baseline were selected from privately insured claims database 80.7 million enrollees. Index dates defined as the first prescription/administration immunosuppressant, biologic between 2003 2009....
Abstract Wind turbines can exhibit flutter-like edgewise instabilities past a critical rotor speed. These are dominated by an edge-torsion coupling due to flapwise blade deflection. This paper experimentally validates the predicted stability limit of 7 MW machine. State art simulation software is used compare against recorded test data and characterize observed flutter mechanism. The speed at which occur in field measurements be time domain simulations analysis with very good agreement.
Since 1999, many states have experienced a "crisis" in medical malpractice insurance. The median premium increase for internists, general surgeons, and obstetricians-gynecologists increased from 0-2 percent 1996-97 to 17-18 2003, climbing 60 some 2001-02, after adjusting inflation. In December 2001, St. Paul Travelers, which was the largest insurer operating forty-five states, announced its decision withdraw market, citing losses of millions dollars on liability business. Two other major...
Objective To evaluate the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) compared with symptom-based management (CM) in patients Crohn’s disease (CD) naïve to immunosuppressants biologics using a UK public payer perspective. Design A regression model estimated weekly CD Activity Index (CDAI)-based transition matrices (remission: CDAI <150, moderate: ≥150 <300, severe: ≥300 <450, very ≥450) based on Effect Tight Control...
Adalimumab is a fully human, monoclonal antibody clinically effective for the treatment of active Crohn's disease. The cost-effectiveness adalimumab versus conventional, nonbiologic pharmacotherapies unknown. This study evaluated in maintenance disease.Trial data from two randomized controlled studies [Crohn's Trial Fully Human Antibody Remission Maintenance (CHARM) and CLinical Assessment Safety Efficacy Studied as Induction Therapy Disease (CLASSIC I)] were analyzed within cost-utility...
This is the first analysis to estimate costs of commercially insured patients with Parkinson's disease (PD) in USA. Prior analyses PD have not examined aged under 65 years, a majority whom are workforce.Our objective was direct and indirect associated age years who newly diagnosed or evidence advanced PD.PD were selected from claims database (N > 12,000,000; 1999-2009); workloss data available for sub-sample enrollees. Newly similar disorders excluded. Patients disease, including ambulatory...
Brexanolone injection (BRX) was approved by the FDA in 2019 for treatment of adult patients with postpartum depression (PPD), but its cost-effectiveness has not yet been evaluated.
Cost-effectiveness data on chimeric antigen receptor (CAR) T cell therapies for relapsed/refractory large B lymphoma (R/R LBCL), accounting inpatient/outpatient site of care (site), are sparse. This payer model compares lifetime costs/benefits CAR cell-treated (axicabtagene ciloleucel [axi-cel], lisocabtagene maraleucel [liso-cel], tisagenlecleucel [tisa-cel]) patients with R/R LBCL in the USA. Three-month post-infusion costs were derived from unit and real-world all-payer (RW) site-specific...